World

Mr. Trump has a different view than Ms. Harris about Mr. Kim Jong-un

Aug 31, 2024

Washington [US], August 31: Former US President and Republican presidential candidate Donald Trump said on August 30 that 'getting along' with North Korean leader Kim Jong-un is a 'good thing'.
During a campaign in Pennsylvania, a key battleground state, Mr Trump once again highlighted his personal relationship with Mr Kim, as he is in a tight race for the White House with his rival, US Vice President and Democratic presidential candidate Kamala Harris.
"I got along with Kim Jong-un of North Korea. Remember I walked through ... the first person to walk through this country," Trump said, apparently referring to his visit to Panmunjom in the inter-Korean demilitarized zone in June 2019, where he briefly crossed the Military Demarcation Line into North Korea, according to Yonhap News Agency.
"We also looked at his nuclear capabilities. It's very substantial... You know, getting along is a good thing, not a bad thing," Mr. Trump stressed.
In her acceptance speech in Chicago on August 22, Ms Harris took aim at Mr Trump, who has long touted his personal relationship with Mr Kim, declaring that she would not befriend someone like Mr Kim Jong-un .
The above statements by the two US presidential candidates show their different visions of diplomacy towards North Korea.
Mr Trump's emphasis on his relationship with Mr Kim has raised the possibility that if re-elected, he could revive his personal diplomacy towards Pyongyang to resolve North Korea's nuclear dilemma.
Meanwhile, Ms. Harris is said to support an approach focused on cooperation with allies and partners to address "evolving threats from North Korea," according to Yonhap.
Source: Thanh Nien Newspaper

More news

Concept Medical Announces Successful SIRONA Trial Results, Demonstrating Sirolimus-Coated Balloon as a Promising Alternative for PAD Treatment

Tampa (Florida) [US], January 7: Concept Medical Inc., a global leader in innovative drug-delivery technology, proudly reports positive outcomes from the SIRONA (Head-to-Head Comparison of SIROlimus versus Paclitaxel Drug-Eluting BallooNAngioplasty in the Femoropopliteal Artery) RCT, which show that its sirolimus-coated balloons (SCB) (MagicTouch -PTA) provide patency and functional benefits on par with paclitaxel-coated balloons for patients suffering from peripheral artery disease (PAD). The 1-year data was presented by Principal Investigator Prof. Ulf Teichgraber at the TCT USA 2024 conference in a Late-Breaking Clinical Trials Session (LBCT). Coverage by TCTMD has highlighted these findings, underscoring sirolimus-based therapy as a viable new option in femoropopliteal interventions.

Jan 07, 2025